Kodiak Sciences reported Phase 3 success for two wet age-related macular degeneration programs, targeting Eylea (aflibercept) with individualized dosing strategies. The company said tarcocimab tedromer (Zenkuda) met primary endpoints and that tabirafusp alpha-tedromer (KSI-501) also achieved noninferiority versus Eylea in its Daybreak study. Kodiak disclosed that Zenkuda’s individualized approach enabled more than half of trial participants to extend injections to every six months, supporting the company’s plan to pursue longer dosing intervals. The biotech said it expects to request FDA approval for wet AMD and expand into additional eye indications later. The twin wins mark a turnaround after a prior Zenkuda Phase 3 readout that failed to match Eylea, repositioning Kodiak for potential market entry with a durability- and injection-frequency-focused profile.